Skip to main content

and
  1. Article

    Open Access

    Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx

    Alexander M. Frankell, Michelle Dietzen, Maise Al Bakir, Emilia L. Lim in Nature (2024)

  2. Article

    Open Access

    Genomic–transcriptomic evolution in lung cancer and metastasis

    Intratumour heterogeneity (ITH) fuels lung cancer evolution, which leads to immune evasion and resistance to therapy1. Here, using paired whole-exome and RNA sequencing data, we investigate intratumour transcript...

    Carlos Martínez-Ruiz, James R. M. Black, Clare Puttick, Mark S. Hill in Nature (2023)

  3. No Access

    Article

    Lung adenocarcinoma promotion by air pollutants

    A complete understanding of how exposure to environmental substances promotes cancer formation is lacking. More than 70 years ago, tumorigenesis was proposed to occur in a two-step process: an initiating step ...

    William Hill, Emilia L. Lim, Clare E. Weeden, Claudia Lee, Marcellus Augustine in Nature (2023)

  4. No Access

    Article

    Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

    Circulating tumour DNA (ctDNA) can be used to detect and profile residual tumour cells persisting after curative intent therapy1. The study of large patient cohorts incorporating longitudinal plasma sampling and ...

    Christopher Abbosh, Alexander M. Frankell, Thomas Harrison, Judit Kisistok in Nature (2023)

  5. Article

    Open Access

    The evolution of non-small cell lung cancer metastases in TRACERx

    Metastatic disease is responsible for the majority of cancer-related deaths1. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited pa...

    Maise Al Bakir, Ariana Huebner, Carlos Martínez-Ruiz, Kristiana Grigoriadis in Nature (2023)

  6. Article

    Open Access

    The evolution of lung cancer and impact of subclonal selection in TRACERx

    Lung cancer is the leading cause of cancer-associated mortality worldwide1. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer...

    Alexander M. Frankell, Michelle Dietzen, Maise Al Bakir, Emilia L. Lim in Nature (2023)

  7. Article

    Open Access

    Antibodies against endogenous retroviruses promote lung cancer immunotherapy

    B cells are frequently found in the margins of solid tumours as organized follicles in ectopic lymphoid organs called tertiary lymphoid structures (TLS)1,2. Although TLS have been found to correlate with improved...

    Kevin W. Ng, Jesse Boumelha, Katey S. S. Enfield, Jorge Almagro, Hongui Cha in Nature (2023)

  8. No Access

    Article

    Using DNA sequencing data to quantify T cell fraction and therapy response

    The immune microenvironment influences tumour evolution and can be both prognostic and predict response to immunotherapy1,2. However, measurements of tumour infiltrating lymphocytes (TILs) are limited by a shorta...

    Robert Bentham, Kevin Litchfield, Thomas B. K. Watkins, Emilia L. Lim in Nature (2021)

  9. No Access

    Article

    Pervasive chromosomal instability and karyotype order in tumour evolution

    Chromosomal instability in cancer consists of dynamic changes to the number and structure of chromosomes1,2. The resulting diversity in somatic copy number alterations (SCNAs) may provide the variation necessary ...

    Thomas B. K. Watkins, Emilia L. Lim, Marina Petkovic, Sergi Elizalde in Nature (2020)

  10. Article

    Open Access

    Escape from nonsense-mediated decay associates with anti-tumor immunogenicity

    Frameshift insertion/deletions (fs-indels) are an infrequent but highly immunogenic mutation subtype. Although fs-indels are degraded through the nonsense-mediated decay (NMD) pathway, we hypothesise that some...

    Kevin Litchfield, James L. Reading, Emilia L. Lim, Hang Xu, Po Liu in Nature Communications (2020)